Victoria’s Chief Health Officer issued a public health alert on Friday 20 June after multiple Melbourne patients were hospitalised with acute liver failure from products labelled as retatrutide. At least six cases of liver toxicity have been linked to the unapproved peptide, with senior doctors at Austin Hospital and Royal Melbourne Hospital sounding the alarm.
The cases are the most serious documented harm from the grey-market retatrutide supply chain in Australia to date.
What Happened
Megan Hancocks, 32, first heard about retatrutide through TikTok and Instagram. During a beauty appointment late last year, she mentioned her interest to a clinician who offered her vials labelled as retatrutide, reportedly sourced from a Chinese manufacturer. She paid in cash.
Ms Hancocks took her first dose on 24 December and a second on 28 December. Less than a week later, she was in acute liver failure at Royal Melbourne Hospital.
Her symptoms were severe: extreme jaundice, constant nausea, vomiting, severe constipation, stomach swelling, and crushing fatigue. She spent a month in hospital. At one point, her medical team began discussing a liver transplant.
Six months on, she is on steroids for liver repair, has been hospitalised multiple times, cannot work, and lives with her mother. “When I look in the mirror I don’t see the same person anymore,” she told the ABC.
It Wasn’t Just One Case
Dr Marie Sinclair, a liver transplant specialist at the Victorian Liver Transplant Unit at Austin Hospital, confirmed she has seen and heard of multiple other patients who became ill after taking products labelled as retatrutide.
A woman in her 20s presented to Austin Hospital emergency in acute liver failure after purchasing vials online that were labelled as retatrutide. Her gym had recommended the product.
A man in his 40s was hospitalised with major kidney injury from extreme dehydration caused by around 40 bouts of diarrhoea per day. He too had been encouraged by his gym to try the drug.
Both the Austin and Royal Melbourne hospitals are now testing the products to determine what they actually contain.
What the Research Says
Retatrutide is a triple agonist developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 trial data presented at ADA 2026 showed weight loss of around 24-25% at 48 weeks. The compound has generated enormous community interest, with many researchers following its progress closely.
But here is the critical point: retatrutide has not been approved by any regulator anywhere in the world. Not the FDA, not the TGA, not the EMA.
A spokesperson for Eli Lilly told the ABC plainly: “Retatrutide is an investigational molecule that has not been approved by any regulator anywhere in the world. No-one can legally sell it for human use.”
The spokesperson added that “counterfeit and black market medicines” are untested, unregulated, and could be deadly.
This means every product currently being sold under the retatrutide name is either counterfeit, mislabelled, or both. There is no legitimate supply chain. The vials Ms Hancocks and the other patients used were not retatrutide from Eli Lilly’s clinical supply - they were unregulated compounds manufactured outside any quality framework.
The Broader Picture
The Victoria health alert lands just 11 days after the TGA made unapproved peptides a priority focus area. The TGA’s chief, Professor Tony Lawler, said the availability of unapproved peptide products has increased along with evidence of consumer risk. Responses may include product seizures, infringement notices, and civil or criminal penalties.
The AMA’s public health committee chair, Dr Michael Bonning, called it “the strongest action the TGA has taken on peptides.”
The TGA, Australian Border Force, and Victorian Police recently seized peptides and performance-enhancing drugs worth an estimated $2 million.
Dr Niloufar Torkamani from Austin Hospital’s Medical Weight Loss Clinic told the ABC that patients regularly email asking to be “upgraded” to retatrutide after seeing it on social media. The demand is real, but so is the risk.
Why This Matters for the Research Community
For anyone following peptide research, this situation highlights a fundamental problem. Retatrutide is genuinely promising - the Phase 3 data is compelling. But the gap between “promising research compound” and “available product” is exactly where people are getting hurt.
The supply chain for grey-market peptides runs through beauticians, gyms, and social media. There is no quality control, no sterility testing, no verification of what is in the vial. The patients hospitalised in Melbourne did not know what they were actually injecting.
If you are interested in the research around retatrutide, the safe path is to follow the clinical trial results as they are published. The compound will go through proper regulatory review. Until then, anything sold as retatrutide is an unregulated product with an unknown composition.
Sources
- Warning issued over counterfeit weight-loss drugs labelled as retatrutide - ABC News Stateline, 19 June 2026
- TGA cracks down on unregulated peptides - ABC News, 10 June 2026
- Victoria Chief Health Officer Health Alert - Victorian Department of Health, 20 June 2026
- Retatrutide Phase 3 data at ADA 2026 - New England Journal of Medicine / ADA 2026
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.